Cat.#: ASSD-103
| Description | DAPI is a blue fluorescent DNA stain which is cell permeant at high concentrations. This is a ready made 1mg/mL staining solution. It is recommended to dilute this solution 1:1000 with your desired buffer for a 1µg/mL working concentration. 0.1µg/mL-10µg/mL is the typical working concentration used in most applications. DAPI also available. |
| Size | 1 mL, 5 mL, |
| Applications | The product is commonly used for cell imaging, cell counting, cell sorting (based on DNA content), apoptosis analysis, and HCA (high content analysis). |
| Chemical Name | 4',6-Diamidino-2-phenylindole dihydrochloride |
| Molecule Weight | 350.24 |
| Molecular formula | C16H15N5.2HCl |
| CAS Number | 28718-90-3 |
| Purity | >98% |
| Form | Pale yellow solution |
| Storage | Store at -20° C |
| Shipping | Shipped at 4°C |
| Important | When using this product for the first time, aliquot the DAPI ready-made solution and store at -20°C to avoid repeated freezing and thawing. Additionally, We strongly recommend storing this solution in the dark and away from light due to the compound's light sensitivity. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-139 | Adenosine A1AR Affinity-Based Probe (AfBP) (AC139) | 50 μg | inquiry |
| ASSD-180 | Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 (AC180) | 1 mg | inquiry |
| ASSD-207 | NBD-X acid (AC207) | 1 g | inquiry |
| ASSD-217 | t-Boc-MTSEA-Fluorescein (AC217) | 10 mg | inquiry |
| ASSD-212 | 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) | 25 mg | inquiry |
| ASSD-122 | Fluorescent β2 antagonist [(±)-propranolol] (AC122) | 500 μg | inquiry |
| ASSD-156 | Crystal Violet (AC156) | 1g, 5g | inquiry |
| ASSD-209 | Tetramethylrhodamine isothiocyanate Isomer R (AC209) | 5 mg, 10 mg | inquiry |
| ASSD-132 | Congo Red (AC132) | 100 mg, 1g | inquiry |
| ASSD-116 | Annexin V-FITC Apoptosis Staining / Detection Kit (AC116) | 1 kit, 100 tests | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.